The Effectiveness and Safety of Hypertonic Citrate Adenine-New (HCA-N) Solution for the Preservation of Kidney Grafts During Kidney Transplantation
A Multicenter, Randomized, Double-blind, Positive-control, Non-inferiority Clinical Trial on the Effectiveness and Safety of Hypertonic Citrate Adenine-New (HCA-N) Solution for the Preservation of Kidney Grafts During Kidney Transplantation
To verify the effectiveness and safety of the HCA-N solution in actual clinical preservation, this study intends to conduct a prospective, randomized, and positive control clinical trial. Using the classic HTK solution as a reference, the study will focus on evaluating the performance of the HCA-N solution in terms of the incidence of delayed recovery of transplant kidney function and the speed of early renal function recovery, with the aim of providing better preservation solution selection and high-level evidence-based guidance for clinical practice in kidney transplantation.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a multicenter, randomized, double-blind, positive-controlled, non-inferiority clinical trial evaluating HCA-N Solution versus Histidine-Tryptophan-Ketoglutarate (HTK) Solution for the preservation of donor kidneys in renal transplantation. HCA-N Solution is a Class III device intended for flushing and preserving isolated kidneys for clinical renal transplantation. Approximately 250 subjects will be enrolled, with 125 subjects in the test group and 125 in the control group, across approximately 20 centers. Donor-recipient pairs must meet the protocol-defined eligibility criteria; eligibility details are provided in the Eligibility Criteria section, and randomization will be 1:1 to the test or control group.
During the screening period (Visit 1 [V1], Day -14 to Day -1 [D-14 to D-1]), potential donors and recipients will be screened for eligibility, informed consent will be obtained, and baseline demographic, medical, immunological, and laboratory information will be collected. The recipient's preoperative baseline estimated glomerular filtration rate (eGFR) value, defined as the last value before transplantation, will be recorded.
On surgery day (Visit 2 [V2], Day 0 [D0]), enrollment and randomization will occur. Vital signs will be recorded, renal transplantation surgery will be performed, and the donor kidney will be flushed and preserved using the assigned preservation solution. Device deficiencies, post-transplant dialysis events, adverse events (AEs), and concomitant treatments will be recorded.
Follow-up visits will occur at Visit 3 (V3, Day 1 [D1]), Visit 4 (V4, Day 3 [D3]), Visit 5 (V5, Day 7 [D7] ± 1), Visit 6 (V6, Day 14 [D14] ± 2), and Visit 7 (V7, Day 28 [D28] ± 3). At these visits, vital signs, laboratory tests including complete blood count, blood biochemistry, and urinalysis, eGFR, dialysis events, adverse events, and concomitant treatments will be recorded. The Day 28 visit will also include physical examination, coagulation function, pregnancy testing for women of childbearing potential, 12-lead electrocardiogram (ECG), and chest computed tomography (CT) or X-ray. Long-term follow-up will collect eGFR, graft survival status, patient survival information, and device-related adverse events.
Efficacy will be assessed primarily by the occurrence of delayed graft function (DGF) after transplantation, with additional renal function parameters within 28 days post-transplantation as specified in the Outcome Measures section. Safety will be evaluated through AEs, serious adverse events (SAEs), vital signs, physical examination, laboratory parameters, ECG, and other protocol-specified assessments.
Statistical analysis will be performed according to prespecified analysis sets. For the primary endpoint, between-group comparisons will use chi-square test, corrected chi-square test, or Fisher's exact test as appropriate, with 95% confidence intervals calculated. Binary secondary endpoints will be analyzed using similar categorical methods. Time-to-event endpoints will be analyzed using the Kaplan-Meier method, including median time, 25%/75% percentiles, 95% confidence intervals, and Kaplan-Meier curves. Continuous eGFR changes from baseline at Days 1, 3, 7, 14, and 28 post-transplantation will be summarized descriptively by group and compared using t-test or rank-sum test as appropriate. Safety analyses will be based on the Safety Set (SS) and will summarize AEs and SAEs by number of events, number of subjects, and incidence rates; AEs will be summarized by severity, System Organ Class (SOC)/Preferred Term (PT), and relationship to the study product. Physical examination, vital signs, 12-lead ECG, and laboratory results will be summarized descriptively.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430071
- Zhongnan Hospital of Wuhan University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Recipients must meet all of the following criteria:
- Age 18 to 65 years (inclusive), regardless of gender.
- Diagnosed as eligible for allogeneic renal transplantation and willing to undergo allogeneic renal transplantation.
- Understand and agree to comply with the study requirements and voluntarily sign the informed consent form.
- Require renal transplantation and be first-time transplant recipients.
Donors must meet all of the following criteria:
- Donor kidney source aged 18 to 65 years (inclusive), regardless of gender.
- Donor's last serum creatinine before kidney procurement < 2 mg/dL (177 μmol/L), and not having received hemodialysis.
Exclusion Criteria:
Recipients meeting any of the following criteria will be excluded:
- Planned for dual kidney transplantation.
- Planned for multi-organ combined transplantation.
- History of previous organ transplantation.
- Concurrent severe diseases, such as severe hepatic impairment, cardiopulmonary insufficiency, coagulation disorders, etc.
- Diagnosis of malignant tumor within 5 years prior to enrollment (except for adequately treated cervical carcinoma in situ, localized cutaneous squamous cell carcinoma, basal cell carcinoma, prostate cancer not requiring antitumor therapy, thyroid cancer, breast ductal carcinoma in situ, and urothelial carcinoma below T1 stage).
- Panel reactive antibody (PRA) > 10%.
- Pregnant or lactating women.
- Participation in other drug or device clinical trials within 3 months prior to enrollment.
- Donors meeting any of the following criteria will be excluded:
- Donor has received renal replacement therapy (hemodialysis or continuous renal replacement therapy [CRRT]) prior to screening.
- Donor has infectious diseases unsuitable for transplantation.
Other requirements:
- ABO blood group system incompatibility between donor and recipient.
- Donor kidney warm ischemia time > 10 minutes, or cold ischemia time > 24 hours.
- Mechanical perfusion preservation required as assessed by the investigator.
- Other conditions that the investigator deems inappropriate for participation in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Evaluate the Efficacy and Safety of HCA-N Solution for Preservation of Donor Kidneys
To evaluate the safety and efficacy of HCA-N Solution for the preservation of donor kidneys in renal transplantation, through a comparative study with HTK Solution in kidney organ transplantation. |
Experimental Group using HCA-N Solution for the preservation of donor kidneys in renal transplantation |
|
Sham Comparator: comparative with HTK Solution in kidney organ transplantation.
The commonly used methods in clinical practice |
control group using HTK Solution in kidney organ transplantation |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of subjects experiencing delayed graft function (DGF) post-transplantation.
Time Frame: Baseline at Days 1, 3, 7, 14, and 28 post-transplantation
|
DGF is defined as the need for dialysis within 1 week after transplantation. |
Baseline at Days 1, 3, 7, 14, and 28 post-transplantation
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- QD-QGBC-2512
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The clinical project is underway and the data must be kept confidential.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.